Almirall's "Perfect Storm": How Will It Recover?
Executive Summary
Changes in business processes in the US, and the launch of new products including a competitively priced Skilarence in the EU, are expected to help Almirall recover from setbacks over the coming months.
You may also be interested in...
Almirall To Position Oral DMF For Psoriasis Ahead Of EU Biologics Use
Almirall aims to start selling its unpatented fumaric acid derivative throughout Europe in the third quarter for treating plaque psoriasis, but will not seek approval for the medicine in the US.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.